30 years of innovation, education, commitment, and proximity.
Developing treatments for patients suffering from chronic conditions like glaucoma or dry eye disease, which affect the lives of millions of people worldwide, or responding to the WHO’s call by developing an antibiotic to treat trachoma, a blinding but curable disease that particularly affects children in Africa.
This is what Théa is all about, and it’s what each of our 1,900 employees in our 35 subsidiaries strives for every day. As pioneers of preservative-free treatments and 100% dedicated to ophthalmology, we are proud to have made significant advancements in numerous therapeutic areas.
By fostering knowledge sharing, we are also committed to supporting the continuous education of healthcare professionals to address health challenges around the globe. With Jean-Frédéric Chibret, President of the Théa Group, and Henri Chibret, its founder, we are driven by the entrepreneurial spirit that is part of our DNA.
This is what makes Théa unique. Because there is still so much to do and discover, particularly in many diseases for which there are currently no effective treatments.
Thank you all for joining us on this scientific and human adventure!
Together, let's open our eyes wide to the next 30 years!